<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Vulnerable</title>
	<atom:link href="http://www.tapanray.in/tag/vulnerable/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma’s Dual Challenge &#8211; To Save Lives And Livelihood</title>
		<link>http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-dual-challenge-to-save-lives-and-livelihood</link>
		<comments>http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/#comments</comments>
		<pubDate>Mon, 29 Jun 2020 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[comparative]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[dexamethasone]]></category>
		<category><![CDATA[dual]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[favipiravir]]></category>
		<category><![CDATA[herd]]></category>
		<category><![CDATA[immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remdesivir]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[vaccine-induced]]></category>
		<category><![CDATA[Vulnerable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10146</guid>
		<description><![CDATA[“Jaan hai to jahan hai” (If you have life, you have the world). Prime Minister Modi - with a skillful tweak, used the couplet of the 18th century poet - Mir Taqi Mir, while announcing the criticality of 21-day national lockdown from March 24, 2020 due &#8230; <a href="http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shifting Pharma Supply Chain Strategy From Global To Local</title>
		<link>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shifting-pharma-supply-chain-strategy-from-global-to-local</link>
		<comments>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/#comments</comments>
		<pubDate>Mon, 08 Jun 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reevaluating]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vulnerability]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10120</guid>
		<description><![CDATA[Alongside large-scale disruptions of many critical industrial operations, Covid-19 global pandemic took the wind out of the sail of pharma supply chain, as well, at the very onset of lockdowns. This happened in many countries around the world, including the &#8230; <a href="http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals with Therapeutic Claims: A Vulnerable Growing Bubble Protected by Faith and Hope of Patients</title>
		<link>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients</link>
		<comments>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/#comments</comments>
		<pubDate>Mon, 27 Aug 2012 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Bubble]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Claims]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[Faith]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hope]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Protected]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=45</guid>
		<description><![CDATA[Today a growing number of particularly the aging population wants to live a healthy life without consuming much of chemical drugs, which in turn is becoming a key growth driver for nutraceutical products across the world. Further, increasing interest towards &#8230; <a href="http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
